Delving into the Latest Updates on Curadim Pharma Co., Ltd. with Synapse

概览

关联

1

项与 Curadim Pharma Co., Ltd. 相关的药物

CP-1050

靶点-

作用机制-

在研机构-

原研机构

Curadim Pharma Co., Ltd.

在研适应症-

非在研适应症-

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

2

项与 Curadim Pharma Co., Ltd. 相关的临床试验

NCT03468413

/ Unknown status临床1期

A Randomised, First-in-human, Double-blinded, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CP1050 in Healthy Subjects; Including the Effect of Food and Gender on the Pharmacokinetics and Pharmacodynamics of a Single Dose of CP1050 in Healthy Subjects

This is a Phase I, first-in-human, double-blind, single-centre, randomised, placebo-controlled, single and multiple oral dose study in healthy subjects conducted in 4 parts (Part 1; Single-ascending dose, Part 2; Food-effect evaluation, Part 3; Gender-effect evaluation, Part 4; Multiple-ascending dose).

开始日期2018-02-05

申办/合作机构

Curadim Pharma Co., Ltd.

JPRN-UMIN000031175

/ Completed临床1期

A randomised, first-in-human, double-blinded, placebo-controlled study to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CP1050 in healthy subjects; including the effect of food and gender on the pharmacokinetics and pharmacodynamics of a single dose of CP1050 in healthy subjects - A randomised, first-in-human, double-blinded, placebo-controlled study of CP1050 in healthy subjects

开始日期2018-02-05

申办/合作机构

Curadim Pharma Co., Ltd.

100 项与 Curadim Pharma Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Curadim Pharma Co., Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Curadim Pharma Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Curadim Pharma Co., Ltd. 相关的转化医学

登录后查看更多信息